High density lipoprotein causes
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein causes On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein causes |
|
Risk calculators and risk factors for High density lipoprotein causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Causes
- HDL cholesterol is a positive cardiac risk factor if
- HDL < 35 mg/dL
- Total cholesterol to HDL ratio in > 5.0 (in men)
- Total cholesterol to HDL ratio in > 4.5 (in women)
- Negative cardiac risk factor if HDL > 60 mg/dL
Decreased
- Apolipoprotein deficiency: Hypoalphalipoproteinemia can be of three types.
- Impaired synthesis of apo A-1: apo A-I deficiency, apo A-1/C-3 deficiency, apo A-1 structural variants
- Increased catabolism: familial HDL deficiency or Tangier disease
- Enzymatic changes: genetic, reduced activity of lipoprotein lipase, elevated liver triglyceride lipase activity, LCAT (lecithin cholesterol acyltransferase) deficiency
- Liver disease
- Menopause
- Obesity[1]
- Puberty in males
- Uremia[2]
- Familial combined hypolipidemia[3]
- Elevated CETP (cholesteryl ester transfer protein) activity: Polymorphism of the gene TaqIB (CETP gene) is known to be associated with variations in the plasma concentrations of CETP. A gene variant called TaqIB1 is associated with a higher CETP concentration and lower HDL-C levels in the plasma. Two other mutations that result in similar findings are A373P and R451Q.[4][5][6][7]
- Smoking
- Lack of physical exercise[1]
- High carbohydrate diet
Increased
- Drugs
- Moderate alcohol intake
- Regular aerobic exercise
- Weight loss
References
- ↑ 1.0 1.1 1.2 Elme A, Utriainen M, Kellokumpu-Lehtinen P; et al. (2013). "Obesity and physical inactivity are related to impaired physical health of breast cancer survivors". Anticancer Res. 33 (4): 1595–602. PMID 23564803. Unknown parameter
|month=ignored (help) - ↑ Khoueiry G, Abdallah M, Saiful F; et al. (2013). "High-density lipoprotein in uremic patients: metabolism, impairment, and therapy". Int Urol Nephrol. doi:10.1007/s11255-012-0366-y. PMID 23443874. Unknown parameter
|month=ignored (help) - ↑ Minicocci I, Montali A, Robciuc MR; et al. (2012). "Mutations in the ANGPTL3 gene and familial combined hypolipidemia: a clinical and biochemical characterization". J. Clin. Endocrinol. Metab. 97 (7): E1266–75. doi:10.1210/jc.2012-1298. PMID 22659251. Unknown parameter
|month=ignored (help) - ↑ Pachocka LM, Włodarczyk M, Nowicka G, Kłosiewicz-Latoszek L, Wolańska D, Stolarska I (2012). "[CETP gene TaqIB polymorphism and plasma lipids in patients with overweight and obesity]". Rocz Panstw Zakl Hig (in Polish). 63 (2): 149–54. PMID 22928361.
- ↑ Rahimi Z, Nourozi-Rad R, Rahimi Z, Parsian A (2012). "Strong interaction between T allele of endothelial nitric oxide synthase with B1 allele of cholesteryl ester transfer protein TaqIB highly elevates the risk of coronary artery disease and type 2 diabetes mellitus". Hum. Genomics. 6: 20. doi:10.1186/1479-7364-6-20. PMC 3500247. PMID 23157875.
- ↑ Li YY, Wu XY, Xu J, Qian Y, Zhou CW, Wang B (2013). "Apo A5 -1131T/C, FgB -455G/A, -148C/T, and CETP TaqIB gene polymorphisms and coronary artery disease in the Chinese population: a meta-analysis of 15,055 subjects". Mol. Biol. Rep. 40 (2): 1997–2014. doi:10.1007/s11033-012-2257-9. PMID 23129316. Unknown parameter
|month=ignored (help) - ↑ Rejeb J, Omezzine A, Boumaiza I; et al. (2012). "Four polymorphisms of cholesteryl ester transfer protein gene and coronary stenosis in a Tunisian population". J Cardiovasc Med (Hagerstown). 13 (9): 546–53. doi:10.2459/JCM.0b013e3283569b24. PMID 22854712. Unknown parameter
|month=ignored (help)